On the other hand, the ORIENT-16 trial (ClinicalTrials.gov, NCT03745-170) showed that CapeOX combined with sintilimab improved the prognosis of all unresectable advanced gastric cancer patients in first-line therapy regardless of the expression of PD-L1. This evidence concerns the gene CD274 and gastric cancer.